Integrated Pharmacokinetic-Pharmacodynamic (PK/PD) Model to Evaluate the in Vivo Antimicrobial Activity of Marbofloxacin Against Pasteurella Multocida in Piglets

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2017 Jun 17

PMID 28619095

Citations 9

Authors

Qing Lin Zeng

Xian Mei

Jia Su

Xiao Hong Li

Wen Guang Xiong

Yan Lu

Zhen Ling Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Marbofloxacin is a veterinary fluoroquinolone with high activity against Pasteurella multocida. We evaluated it's in vivo activity against P. multocida based on in vivo time-kill data in swine using a tissue-cage model. A series of dosages ranging from 0.15 to 2.5 mg/kg were administered intramuscularly after challenge with P. multocida type B, serotype 2.

Results: The ratio of the 24 h area under the concentration-time curve divided by the minimum inhibitory concentration (AUCTCF/MIC) was the best PK/PD index correlated with the in vivo antibacterial effectiveness of marbofloxacin (R2 = 0.9279). The AUCTCF/MIC necessary to achieve a 1-log CFU/ml reduction and a 3-log CFU/ml (90% of the maximum response) reduction as calculated by an inhibitory sigmoid E model were 13.48 h and 57.70 h, respectively.

Conclusions: Marbofloxacin is adequate for the treatment of swine infected with P. multocida. The tissue-cage model played a significant role in achieving these PK/PD results.

Citing Articles

Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin Against in Dogs.

Jeong J, Kim J, Kim J, Kim C, Chung E, Boo S Pathogens. 2025; 13(12.

PMID: 39770380 PMC: 11679838. DOI: 10.3390/pathogens13121121.

Pharmacokinetic/pharmacodynamic integration of tilmicosin against in a piglet tissue cage model.

Chen Y, Ji X, Zhang S, Wang W, Zhang H, Ding H Front Vet Sci. 2023; 10:1260990.

PMID: 37732140 PMC: 10507324. DOI: 10.3389/fvets.2023.1260990.

Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against in a Porcine Tissue Cage Infection Model.

Yao L, Yang L, Ling Y, Wei Y, Shen X, Ding H Front Vet Sci. 2022; 9:822432.

PMID: 35419449 PMC: 8995781. DOI: 10.3389/fvets.2022.822432.

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models.

Zhang L, Xie H, Wang Y, Wang H, Hu J, Zhang G Front Vet Sci. 2022; 9:860472.

PMID: 35400105 PMC: 8989418. DOI: 10.3389/fvets.2022.860472.

Genome-Wide Differential Expression Profiling of Pulmonary circRNAs Associated With Immune Reaction to in Goats.

Chen Q, Zhang Z, Chen S, Chen J, Cheng Y, Liu A Front Vet Sci. 2021; 8:615405.

PMID: 34235193 PMC: 8256745. DOI: 10.3389/fvets.2021.615405.

References

Vilalta C, Giboin H, Schneider M, El Garch F, Fraile L . Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin in the treatment of Haemophilus parasuis and Actinobacillus pleuropneumoniae infections in nursery and fattener pigs using Monte Carlo simulations. J Vet Pharmacol Ther. 2014; 37(6):542-9. DOI: 10.1111/jvp.12134. View

Appelbaum P, Hunter P . The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2001; 16(1):5-15. DOI: 10.1016/s0924-8579(00)00192-8. View

Ding H, Li Y, Chen Z, Rizwan-Ul-Haq M, Zeng Z . Plasma and tissue cage fluid pharmacokinetics of marbofloxacin after intravenous, intramuscular, and oral single-dose application in pigs. J Vet Pharmacol Ther. 2010; 33(5):507-10. DOI: 10.1111/j.1365-2885.2010.01164.x. View

Kalorey D, Yuvaraj S, Vanjari S, Gunjal P, Dhanawade N, Barbuddhe S . PCR analysis of Pasteurella multocida isolates from an outbreak of pasteurellosis in Indian pigs. Comp Immunol Microbiol Infect Dis. 2007; 31(6):459-65. DOI: 10.1016/j.cimid.2007.06.003. View

Dayao D, Gibson J, Blackall P, Turni C . Antimicrobial resistance in bacteria associated with porcine respiratory disease in Australia. Vet Microbiol. 2014; 171(1-2):232-5. DOI: 10.1016/j.vetmic.2014.03.014. View

El Garch F, de Jong A, Simjee S, Moyaert H, Klein U, Ludwig C . Monitoring of antimicrobial susceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across Europe, 2009-2012: VetPath results. Vet Microbiol. 2016; 194:11-22. DOI: 10.1016/j.vetmic.2016.04.009. View

Pors S, Hansen M, Bisgaard M, Jensen H . Occurrence and associated lesions of Pasteurella multocida in porcine bronchopneumonia. Vet Microbiol. 2011; 150(1-2):160-6. DOI: 10.1016/j.vetmic.2011.01.005. View

MacGowan A, Bowker K . Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int J Antimicrob Agents. 2002; 19(4):291-8. DOI: 10.1016/s0924-8579(02)00027-4. View

Thomas J, Forrest A, Bhavnani S, Hyatt J, Cheng A, Ballow C . Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42(3):521-7. PMC: 105492. DOI: 10.1128/AAC.42.3.521. View

10.

Greko C, Finn M, Franklin A, Bengtsson B . Pharmacokinetic/pharmacodynamic relationship of danofloxacin against Mannheimia haemolytica in a tissue-cage model in calves. J Antimicrob Chemother. 2003; 52(2):253-7. DOI: 10.1093/jac/dkg339. View

11.

Magyar T, King V, Kovacs F . Evaluation of vaccines for atrophic rhinitis--a comparison of three challenge models. Vaccine. 2002; 20(13-14):1797-802. DOI: 10.1016/s0264-410x(02)00023-3. View

12.

Andes D, Craig W . In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 1998; 42(9):2375-9. PMC: 105836. DOI: 10.1128/AAC.42.9.2375. View

13.

Dorey L, Hobson S, Lees P . Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media. Res Vet Sci. 2016; 111:43-48. DOI: 10.1016/j.rvsc.2016.11.001. View

14.

de Jong A, Thomas V, Simjee S, Moyaert H, El Garch F, Maher K . Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath study. Vet Microbiol. 2014; 172(1-2):202-15. DOI: 10.1016/j.vetmic.2014.04.008. View

15.

Holst E, Rollof J, Larsson L, Nielsen J . Characterization and distribution of Pasteurella species recovered from infected humans. J Clin Microbiol. 1992; 30(11):2984-7. PMC: 270564. DOI: 10.1128/jcm.30.11.2984-2987.1992. View

16.

Aalbaek B, Eriksen L, Rimler R, Leifsson P, Basse A, Christiansen T . Typing of Pasteurella multocida from haemorrhagic septicaemia in Danish fallow deer (Dama dama). APMIS. 1999; 107(10):913-20. View

17.

Shan Q, Wang J, Yang F, Ding H, Liang C, Lv Z . Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue-cage model in yellow cattle. J Vet Pharmacol Ther. 2013; 37(3):222-30. DOI: 10.1111/jvp.12078. View

18.

Frimodt-Moller N . How predictive is PK/PD for antibacterial agents?. Int J Antimicrob Agents. 2002; 19(4):333-9. DOI: 10.1016/s0924-8579(02)00029-8. View

19.

Gunderson B, Ross G, Ibrahim K, Rotschafer J . What do we really know about antibiotic pharmacodynamics?. Pharmacotherapy. 2001; 21(11 Pt 2):302S-318S. DOI: 10.1592/phco.21.18.302s.33905. View

20.

Xiao X, Sun J, Yang T, Fang X, Wu D, Xiong Y . In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model. Antimicrob Agents Chemother. 2015; 59(7):3754-60. PMC: 4468724. DOI: 10.1128/AAC.00200-15. View